These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37088317)
1. Nanobiotechnological approaches in osteosarcoma therapy: Versatile (nano)platforms for theranostic applications. Jiang Y; He K Environ Res; 2023 Jul; 229():115939. PubMed ID: 37088317 [TBL] [Abstract][Full Text] [Related]
2. Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview. Desai SA; Manjappa A; Khulbe P J Egypt Natl Canc Inst; 2021 Feb; 33(1):4. PubMed ID: 33555490 [TBL] [Abstract][Full Text] [Related]
3. Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment. Gu X; Ding J; Zhang Z; Li Q; Zhuang X; Chen X Curr Pharm Des; 2015; 21(36):5187-97. PubMed ID: 26412359 [TBL] [Abstract][Full Text] [Related]
4. Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma. Yu T; Cai Z; Chang X; Xing C; White S; Guo X; Jin J Orthop Surg; 2023 Sep; 15(9):2244-2259. PubMed ID: 37403654 [TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoparticles for the treatment and diagnosis of osteosarcoma. Yuan P; Min Y; Zhao Z Biomater Adv; 2023 Aug; 151():213466. PubMed ID: 37229927 [TBL] [Abstract][Full Text] [Related]
6. Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes. Liang W; Dong Y; Shao R; Zhang S; Wu X; Huang X; Sun B; Zeng B; Zhao J J Drug Target; 2022 Jun; 30(5):463-475. PubMed ID: 34962448 [TBL] [Abstract][Full Text] [Related]
7. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways. Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906 [TBL] [Abstract][Full Text] [Related]
8. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. Shi P; Cheng Z; Zhao K; Chen Y; Zhang A; Gan W; Zhang Y J Nanobiotechnology; 2023 Mar; 21(1):103. PubMed ID: 36944946 [TBL] [Abstract][Full Text] [Related]
9. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. Martínez-Carmona M; Lozano D; Colilla M; Vallet-Regí M Acta Biomater; 2018 Jan; 65():393-404. PubMed ID: 29127069 [TBL] [Abstract][Full Text] [Related]
10. Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma. Zeng WN; Yu QP; Wang D; Liu JL; Yang QJ; Zhou ZK; Zeng YP J Nanobiotechnology; 2021 Mar; 19(1):79. PubMed ID: 33740998 [TBL] [Abstract][Full Text] [Related]
11. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma. Qiu R; Sun D; Bai Y; Li J; Wang L Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647 [TBL] [Abstract][Full Text] [Related]
12. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. Santos A; Domingues C; Jarak I; Veiga F; Figueiras A Eur J Pharm Biopharm; 2022 Jan; 170():91-111. PubMed ID: 34896571 [TBL] [Abstract][Full Text] [Related]
13. Developing a Versatile Multiscale Therapeutic Platform for Osteosarcoma Synergistic Photothermo-Chemotherapy with Effective Osteogenicity and Antibacterial Capability. Ma Y; Jiang L; Hu J; Zhu E; Zhang N ACS Appl Mater Interfaces; 2022 Oct; 14(39):44065-44083. PubMed ID: 36125961 [TBL] [Abstract][Full Text] [Related]
14. Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma. González-Fernández Y; Brown HK; Patiño-García A; Heymann D; Blanco-Prieto MJ Cancer Lett; 2018 Aug; 430():193-200. PubMed ID: 29802930 [TBL] [Abstract][Full Text] [Related]
15. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma. Huang X; Wu W; Yang W; Qing X; Shao Z Colloids Surf B Biointerfaces; 2020 Jun; 190():110891. PubMed ID: 32114271 [TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model. Lenna S; Bellotti C; Duchi S; Martella E; Columbaro M; Dozza B; Ballestri M; Guerrini A; Sotgiu G; Frisoni T; Cevolani L; Varchi G; Ferrari M; Donati DM; Lucarelli E J Exp Clin Cancer Res; 2020 Feb; 39(1):40. PubMed ID: 32087737 [TBL] [Abstract][Full Text] [Related]
17. Current approaches in tissue engineering-based nanotherapeutics for osteosarcoma treatment. Shanmugavadivu A; Lekhavadhani S; Miranda PJ; Selvamurugan N Biomed Mater; 2024 Feb; 19(2):. PubMed ID: 38324905 [TBL] [Abstract][Full Text] [Related]
18. Blocking miR-27a-3p sensitises Taxol resistant osteosarcoma cells through targeting Fbxw7. Lu B; Feng Z; Fan B; Shi Y Bull Cancer; 2021 Jun; 108(6):596-604. PubMed ID: 33863546 [TBL] [Abstract][Full Text] [Related]
19. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients. Klangjorhor J; Phanphaisarn A; Teeyakasem P; Chaiyawat P; Phinyo P; Settakorn J; Theera-Umpon N; Pruksakorn D Cancer Chemother Pharmacol; 2020 Jun; 85(6):1165-1176. PubMed ID: 32476109 [TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma: Conventional treatment vs. gene therapy. Tan ML; Choong PF; Dass CR Cancer Biol Ther; 2009 Jan; 8(2):106-17. PubMed ID: 19098456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]